Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

• Status: Terminated
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A Double-Blind Placebo-Controlled Random Order Crossover Pilot Study of Iloperidone for Symptoms of Arousal in PTSD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: Novartis Pharmaceuticals
• Treatments: Iloperidone

Criteria

Inclusion Criteria:

• PTSD diagnosis

Exclusion Criteria:

• Pregnancy

• Traumatic Brain Injury greater than mild

• Primary sleep disorder

• Caffeinism

• Active substance use disorder

• Active suicidal risk

• Antipsychotic medication, antibiotics, sedatives, some antihypertensive or antiarrhythmic medication